• 1
    Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin. 2010; 60: 277-300.
  • 2
    Bonnefoi H, A'Hern RP, Fisher C, et al. Natural history of stage IV epithelial ovarian cancer. J Clin Oncol. 1999; 17: 767-775.
  • 3
    McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med. 1996; 334: 1-6.
  • 4
    Cancer Therapy Evaluation Program (CTEP). Rapid Communication: Solicitation for Letters of Intent: E7389, Halichondrin B Analog (NSC 707389). Bethesda, MD: CTEP, National Cancer Institute; 2005.
  • 5
    Towle MJ, Salvato KA, Budrow J, et al. In vitro and in vivo anticancer activities of synthetic macrocyclic ketone analogues of halichondrin B. Cancer Res. 2001; 61: 1013-1021.
  • 6
    Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000; 92: 205-216.
  • 7
    Rustin GJ, Nelstrop AE, McClean P, et al. Defining response of ovarian carcinoma to initial chemotherapy according to serum CA 125. J Clin Oncol. 1996; 5: 1545-1551.
  • 8
    Rustin GJ, Bast RC Jr, Kelloff GJ, et al. Use of CA-125 in clinical trial evaluation of new therapeutic drugs for ovarian cancer. Clin Cancer Res. 2004; 10: 3919-3926.
  • 9
    Simon R. Optimal 2-stage designs for phase II clinical trials. Control Clin Trials. 1989; 10: 1-10.
  • 10
    Koyama T, Chen H. Proper inference from Simon's 2-stage designs. Stat Med. 2008; 27: 3145-3154.
  • 11
    Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958; 53: 457-481.
  • 12
    Seshan VE. Clinfun: Clinical Trial Design and Data Analysis Functions. R package version 0.9.6. 2010. Available at: Accessed August 2011.
  • 13
    Gordon AN, Fleagle JT, Guthrie D, et al. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol. 2001; 19: 3312-3322.
  • 14
    Mutch DG, Orlando M, Goss T, et al. Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer. J Clin Oncol. 2007; 25: 2811-2818.
  • 15
    Markman M, Kennedy A, Webster K, et al. Phase 2 trial of liposomal doxorubicin (40 mg/m2) in platinum/paclitaxel-refractory ovarian and fallopian tube cancers and primary carcinoma of the peritoneum. Gynecol Oncol. 2000; 78( 3 pt 1): 369-372.
  • 16
    Gordon AN, Granai CO, Rose PG, et al. Phase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer. J Clin Oncol. 2000; 18: 3093-3100.
  • 17
    Twelves C, Loesch D, Blum JL, et al; on behalf of the Study 305 investigators. A phase III study (EMBRACE) of eribulin mesylate versus treatment of physician's choice in patients with locally recurrent or metastatic breast cancer previously treated with an anthracycline and a taxane [abstract]. J Clin Oncol. 2010; 28: 18S. Abstract CRA1004.
  • 18
    Cortes J, Vahdat L, Blum JL, et al. Phase II study of the halichondrin B analog eribulin mesylate in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline, a taxane, and capecitabine. J Clin Oncol. 2010; 28: 3922-3928.
  • 19
    Sabbatini P, Spriggs D, Aghajanian C, et al. Consolidation strategies in ovarian cancer: observations for future clinical trials. Gynecol Oncol. 2010; 116: 66-71.